drugset / Trial / NCT06311578
A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to determine the safety, feasibility, recommended dose(s) and regimen(s) of JNJ-87704916 as monotherapy and in combination with cetrelimab.
Timeline
- Start
- 2024-04-10
- Primary completion
- 2028-11-08
- Completion
- 2033-02-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetrelimab | Monoclonal antibody | — | — |
| Subject | JNJ-87704916 | Unknown | — | Intrathecal |